GYRE THERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Mar 13, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 13, 2026

GYRE$4.65-2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	December 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$37,070	$11,813
Short-term bank deposits	15,355	14,858
Notes receivable	5,638	4,373
Accounts receivable, net	31,078	19,589
Other receivables from GNI	230	230
Inventories	10,171	6,337
Prepaid assets	1,338	1,189
Receivable from GCBP	—	4,961
Other current assets	1,489	1,436
Total current assets:	102,369	64,786
Property and equipment, net	23,599	23,880
Intangible assets, net	4,727	273
Right-of-use assets	1,131	1,818
Land use rights, net	1,425	1,432
Deferred tax assets	6,873	5,619
Long-term certificates of deposit	23,516	24,568
Other assets, noncurrent	2,492	3,030
Total assets	$166,132	$125,406
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$124	$108
Contract liabilities	14	61
Due to related parties	227	227
Accrued expenses and other current liabilities	14,345	10,615
Income tax payable	2,940	2,831
Operating lease liabilities, current	636	713
CVR derivative liability	—	4,961
Total current liabilities:	18,286	19,516
Operating lease liabilities, noncurrent	303	885
Deferred government grants	852	928
Warrant liability, noncurrent	2,961	5,668
Other noncurrent liabilities	1,448	7
Total liabilities	$23,850	$27,004
Commitments and Contingencies (Note 11)
Stockholders’ equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 91,314,007 shares and 86,307,544 shares issued and outstanding at December 31, 2025 and 2024, respectively	91	86
Additional paid-in capital	172,047	136,185
Statutory reserve	3,098	3,098
Accumulated deficit	(68,426)	(73,453)
Accumulated other comprehensive loss	(779)	(2,597)
Total Gyre stockholders’ equity	106,031	63,319
Noncontrolling interest	36,251	35,083
Total equity	142,282	98,402
Total liabilities and stockholders' equity	$166,132	$125,406

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.